This site is intended for healthcare professionals
Journals
  • Home
  • /
  • Journals
  • /
  • Breast Cancer
  • /
  • Evidence to date: talazoparib in the treatment of ...
Journal

Evidence to date: talazoparib in the treatment of breast cancer.

Read time: 1 mins
Published:2nd Jul 2019
Author: Exman P, Barroso-Sousa R, Tolaney SM.
Availability: Free full text
Ref.:Onco Targets Ther. 2019;12:5177-5187.
DOI:10.2147/OTT.S184971

Approximately 5-10% of all patients diagnosed with breast cancer have germline BRCA1/2 mutations, which make their disease more susceptible to DNA-damaging agents and a new class of drugs known as poly(ADP-ribose) polymerase (PARP) inhibitors. Talazoparib is a new PARP inhibitor that has been recently approved for use in patients with metastatic breast cancer with germline BRCA mutations after a phase III trial showed superior progression-free survival when compared to standard chemotherapy. In this review, we analyze the development of talazoparib as well as its safety profile and the potential role of the combination therapy with standard cytotoxic drugs and with novel therapies.

 

Read abstract on library site

Access full article